A group of novel VEGF splice variants as alternative therapeutic targets in renal cell carcinoma.

ABSTRACT: The efficacy of anti-angiogenic treatment by targeting VEGF/VEGF receptors in metastatic clear cell renal cell carcinoma (ccRCC) varies from patient to patient. Discovering the reasons behind this variability could lead to the identification of relevant therapeutic targets. Thus, we investigated the novel splice variants of VEGF that are less efficiently inhibited by anti-VEGF/VEGFR targeting than the conventional isoforms. By in silico analysis, we identified a novel splice acceptor in the last intron of the VEGF gene resulting in an insertion of 23 bp in VEGF mRNA. Such an insertion can shift the open-reading frame in previously described splice variants of VEGF (VEGF_XXX ), leading to a change in the C-terminal part of the VEGF protein. Next, we analysed the expression of thes

SUBMITTER: Montemagno C 

PROVIDER: S-EPMC10323879 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature